Firebrick Pharma Ltd (FRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Firebrick Pharma Ltd (FRE) has a cash flow conversion efficiency ratio of -0.543x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.05 Million ≈ $-745.48K USD) by net assets (AU$1.94 Million ≈ $1.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FRE equity financing ratio to measure how much of total assets are equity-financed.
Firebrick Pharma Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Firebrick Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Firebrick Pharma Ltd (FRE) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Firebrick Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Firebrick Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KC Property PLC
BK:KC
|
-0.185x |
|
OurLiving AB
ST:OURLIV
|
-4.139x |
|
Purple Biotech Ltd
TA:PPBT
|
-0.033x |
|
PVW Resources Ltd
AU:PVW
|
-1.696x |
|
Emico Holdings Bhd
KLSE:9091
|
0.149x |
|
Eversafe Rubber Bhd
KLSE:0190
|
0.000x |
|
Whitebark Energy Ltd
AU:WBE
|
0.308x |
|
Elkop SA
WAR:EKP
|
0.043x |
Annual Cash Flow Conversion Efficiency for Firebrick Pharma Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Firebrick Pharma Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Firebrick Pharma Ltd (FRE) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.56 Million ≈ $1.10 Million |
AU$-1.78 Million ≈ $-1.26 Million |
-1.143x | -3.12% |
| 2024-06-30 | AU$2.12 Million ≈ $1.50 Million |
AU$-2.34 Million ≈ $-1.66 Million |
-1.109x | +52.54% |
| 2023-06-30 | AU$2.48 Million ≈ $1.75 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-2.336x | -360.20% |
| 2022-06-30 | AU$8.28 Million ≈ $5.86 Million |
AU$-4.20 Million ≈ $-2.97 Million |
-0.508x | -202.88% |
| 2021-06-30 | AU$11.55 Million ≈ $8.17 Million |
AU$-1.94 Million ≈ $-1.37 Million |
-0.168x | +93.35% |
| 2020-06-30 | AU$390.60K ≈ $276.37K |
AU$-985.01K ≈ $-696.96K |
-2.522x | -155.58% |
| 2019-06-30 | AU$1.08 Million ≈ $763.34K |
AU$-1.06 Million ≈ $-753.18K |
-0.987x | -- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.